Trexquant Investment LP Takes $129,000 Position in Brainsway Ltd. Sponsored ADR $BWAY

Trexquant Investment LP acquired a new stake in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 13,576 shares of the company’s stock, valued at approximately $129,000. Trexquant Investment LP owned about 0.07% of Brainsway at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cubist Systematic Strategies LLC increased its holdings in Brainsway by 14.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after purchasing an additional 2,446 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Brainsway in the 4th quarter valued at $44,000. Two Sigma Investments LP increased its holdings in shares of Brainsway by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock valued at $875,000 after acquiring an additional 1,786 shares during the period. Two Sigma Advisers LP increased its holdings in shares of Brainsway by 32.6% in the 4th quarter. Two Sigma Advisers LP now owns 60,600 shares of the company’s stock valued at $571,000 after acquiring an additional 14,900 shares during the period. Finally, Valor Management LLC purchased a new position in shares of Brainsway in the 4th quarter valued at $19,838,000. 30.11% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BWAY has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Brainsway in a research note on Monday, August 25th. Northland Securities boosted their target price on Brainsway from $15.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, August 14th. Finally, Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a research note on Sunday, August 17th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $18.00.

Brainsway Stock Up 0.1%

Shares of BWAY stock opened at $15.93 on Thursday. The stock has a market cap of $301.08 million, a PE ratio of 61.27 and a beta of 1.34. The business has a 50-day simple moving average of $13.37 and a 200-day simple moving average of $11.10. Brainsway Ltd. Sponsored ADR has a 52-week low of $7.51 and a 52-week high of $16.25.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings data on Wednesday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.03. The business had revenue of $12.63 million during the quarter, compared to analysts’ expectations of $12.34 million. Brainsway had a return on equity of 8.97% and a net margin of 11.60%. Brainsway has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Brainsway Ltd. Sponsored ADR will post 0.08 earnings per share for the current fiscal year.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.